227 related articles for article (PubMed ID: 34991643)
21. Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine.
Zhigulin AS; Barygin OI
Eur J Pharmacol; 2022 Mar; 919():174795. PubMed ID: 35122868
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists.
Butchi NB; Pourciau S; Du M; Morgan TW; Peterson KE
J Immunol; 2008 Jun; 180(11):7604-12. PubMed ID: 18490763
[TBL] [Abstract][Full Text] [Related]
23. TMPRSS2 Activates Hemagglutinin-Esterase Glycoprotein of Influenza C Virus.
Sato K; Hayashi H; Shimotai Y; Yamaya M; Hongo S; Kawakami K; Matsuzaki Y; Nishimura H
J Virol; 2021 Oct; 95(21):e0129621. PubMed ID: 34406864
[TBL] [Abstract][Full Text] [Related]
24. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
25. Deoxyguanosine is a TLR7 agonist.
Davenne T; Bridgeman A; Rigby RE; Rehwinkel J
Eur J Immunol; 2020 Jan; 50(1):56-62. PubMed ID: 31608988
[TBL] [Abstract][Full Text] [Related]
26. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus).
Zhou ZX; Sun L
Dev Comp Immunol; 2015 Mar; 49(1):113-20. PubMed ID: 25475963
[TBL] [Abstract][Full Text] [Related]
27. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
28. Nafamostat mesilate is an extremely potent inhibitor of human tryptase.
Mori S; Itoh Y; Shinohata R; Sendo T; Oishi R; Nishibori M
J Pharmacol Sci; 2003 Aug; 92(4):420-3. PubMed ID: 12939527
[TBL] [Abstract][Full Text] [Related]
29. IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod).
Jirmo AC; Daluege K; Happle C; Albrecht M; Dittrich AM; Busse M; Habener A; Skuljec J; Hansen G
J Immunol; 2016 Dec; 197(11):4219-4227. PubMed ID: 27799314
[TBL] [Abstract][Full Text] [Related]
30. The Effectiveness and Safety of Nafamostat Mesylate in the Treatment of COVID-19: a Meta-Analysis.
Wei M; Li T; Liu S; Wang Y; Tran C; Ao G
Jpn J Infect Dis; 2024 May; 77(3):182-186. PubMed ID: 38296543
[TBL] [Abstract][Full Text] [Related]
31. TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes.
Hofmann H; Vanwalscappel B; Bloch N; Landau NR
Retrovirology; 2016 Dec; 13(1):83. PubMed ID: 27905985
[TBL] [Abstract][Full Text] [Related]
32. Nafamostat mesilate, a kallikrein inhibitor, prevents pain on injection with propofol.
Iwama H; Nakane M; Ohmori S; Kaneko T; Kato M; Watanabe K; Okuaki A
Br J Anaesth; 1998 Dec; 81(6):963-4. PubMed ID: 10211027
[TBL] [Abstract][Full Text] [Related]
33. Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
Hernández-Mitre MP; Tong SYC; Denholm JT; Dore GJ; Bowen AC; Lewin SR; Venkatesh B; Hills TE; McQuilten Z; Paterson DL; Morpeth SC; Roberts JA
Clin Pharmacokinet; 2022 Oct; 61(10):1331-1343. PubMed ID: 36040613
[TBL] [Abstract][Full Text] [Related]
34. The impact of TLR7 agonist R848 treatment on mast cell phenotype and activity.
Agier J; Brzezińska-Błaszczyk E; Witczak P; Kozłowska E; Żelechowska P
Cell Immunol; 2021 Jan; 359():104241. PubMed ID: 33158544
[TBL] [Abstract][Full Text] [Related]
35. Effects of nafamostat mesilate on 5-hydroxytryptamine release from isolated ileal tissues induced by anti-cancer drugs in rats.
Kikuchi K; Hamaue N; Machida T; Iizuka K; Minami M; Hirafuji M
Biomed Res; 2020; 41(5):253-257. PubMed ID: 33071261
[TBL] [Abstract][Full Text] [Related]
36. Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019.
Kondo M; Nagano M; Yoshida M; Yoshida N; Tagui N; Yoshida M; Sugaya K; Takase H
J Nippon Med Sch; 2021 Dec; 88(6):533-539. PubMed ID: 33692301
[TBL] [Abstract][Full Text] [Related]
37. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenço AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz NP; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings CL; Rothenberg ME; Pöhlmann S; Whelan SPJ; O'Donoghue AJ; Craik CS; Janetka JW
Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34635581
[TBL] [Abstract][Full Text] [Related]
38. Sustained IL-4 priming of macrophages enhances the inflammatory response to TLR7/8 ligand R848.
Banete A; Gee K; Basta S
J Leukoc Biol; 2022 Feb; 111(2):401-413. PubMed ID: 34013552
[TBL] [Abstract][Full Text] [Related]
39. Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma.
Ishizaki M; Tanaka H; Kajiwara D; Toyohara T; Wakahara K; Inagaki N; Nagai H
J Pharmacol Sci; 2008 Nov; 108(3):355-63. PubMed ID: 19008643
[TBL] [Abstract][Full Text] [Related]
40. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma.
Grela F; Aumeunier A; Bardel E; Van LP; Bourgeois E; Vanoirbeek J; Leite-de-Moraes M; Schneider E; Dy M; Herbelin A; Thieblemont N
J Immunol; 2011 Jan; 186(1):284-90. PubMed ID: 21131420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
